title: Nucleoside-sparing antiretroviral regimens.
abstract: Nucleoside reverse transcriptase inhibitors (NRTIs) were the first drugs approved for use as antiretroviral therapy in patients infected with HIV. Despite the introduction of other classes of antiretroviral drugs, they remain an important component of combination regimens as recommended by many treatment guidelines. They also continue to be used in prevention of disease from mother to child, postexposure prophylaxis, and more recently for preexposure prophylaxis. Unfortunately, the toxicities associated with this class of drugs can limit their use. Although NRTI-sparing regimens are not currently recommended for first-line therapy there is an increasing amount of data supporting their use in both treatment-naive and in treatment-experienced patients.
authors.affiliation: Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, USA, delaTorre-pola@cooperhealth.edu.
authors.forename: Pola
authors.initials: P
authors.lastname: de la Torre
authors.forename: Jomy
authors.initials: J
authors.lastname: George
authors.forename: John D
authors.initials: JD
authors.lastname: Baxter